Background {#Sec1}
==========

Numerous challenges confront readers while accessing the literature; these include but are not limited to the enormous volume of published work, the high cost of obtaining articles especially in resource-limited settings \[[@CR1]\], and language constraints when articles are not written in users' language \[[@CR2]\]. The outcome of this has been an over-reliance on abstracts for articles as a one-stop point for most researchers. Abstracts of journal articles or scientific papers often provide readers with an overview of the content of the full article. As a result, researchers tend to rely on abstracts as a concise source of information \[[@CR3]\] and in making decisions on which publications to read in detail \[[@CR4]\]. Furthermore, researchers rely largely on the abstract when deciding whether to include an article in a systematic review \[[@CR5]\]. All these factors make the abstract a key section of the scientific publication. It is, therefore, important that abstracts of articles are consistent with what is reported in the text and capture essential information.

Randomized control trials (RCT) constitute a significant portion of clinical studies and most times are the core component for systematic reviews. However, the quality of reporting of RCTs have over the years attracted many questions, mostly related to consistency and completeness of reports \[[@CR6]\]. The Consolidated Standard for Reporting of Trials (CONSORT) checklist was conceptualized in 1996 to address these issues. Its publication and instant acceptance led to revisions in 2007 and 2010 \[[@CR7], [@CR8]\]. Many journals have adopted the CONSORT checklist, and it has been shown to improve the quality of reporting RCTs \[[@CR9]--[@CR11]\].

The overwhelming acceptance of CONSORT checklist has led to the development of extensions to incorporate other types of RCTs. Due to the need to widen the scope of the checklist, in 2016, the CONSORT extension checklist for abstracts of pilot trials was developed to aid adequate reporting of pilot trials \[[@CR12]\], an important but often neglected arm of medical research \[[@CR13]\].

We conducted this systematic survey to evaluate the quality of reporting of abstracts of pilot RCTs in heart failure published 1990--2016. Heart failure, defined as a clinical condition in which the heart does not pump blood sufficiently or does so at a higher pressure to maintain the body's need \[[@CR14], [@CR15]\], has been a prominent cause of cardiovascular disease burden in Africa in the last two decades \[[@CR16], [@CR17]\]. It has also attracted many clinical trials in the last two decades (1990--2016), most of which were preceded by pilot trials \[[@CR17]\]. The quality reporting is defined as complete reporting of the 16 items in the CONSORT extension checklist.

The aims of this survey are to (1) evaluate the quality of reporting of abstracts of pilot RCTs in the past 26 years (1990--2016), using the CONSORT extension for reporting of abstracts of pilot trials; (2) identify aspects of the checklist that are consistently reported; (3) identify factors associated with better reporting of abstracts; and (4) determine the quality (completeness) of abstracts of pilot trials.

Methods {#Sec2}
=======

Randomized controlled pilot trials in heart failure published from 1 January 1990 to 30 November 2016 were searched for in line with the systematic survey method as previously described \[[@CR17]\]. Abstracts were selected if they were described as random, randomly allocated, and randomized. We searched the MEDLINE (PubMed), Cochrane Controlled Trials Register, Scopus, and African-wide information databases (search strategy in the Additional file [1](#MOESM1){ref-type="media"}). We limited our search to pilot trial reports written in English language only. Two reviewers independently screened the identified papers and those finally selected to assess the quality of reporting of abstracts using the 16 items of CONSORT extension for reporting of abstract of pilot trials. We assigned a score of one to an item on the CONSORT checklist if the item was reported in the abstract. The overall quality of abstract was calculated as the proportion of "yes" responses. We classified abstracts that reported all the 16 items in the CONSORT checklist as adequate quality reporting.

We hypothesized that pilot trials published in high impact journals \[[@CR18]\], published in CONSORT-endorsing journals \[[@CR19], [@CR20]\], those on pharmacological interventions \[[@CR20]\], studies with large sample sizes \[[@CR21]\], and industry-funded studies \[[@CR22]\] would have better reporting quality.

The protocol for this systematic survey \[[@CR17]\] was registered with PROSPERO (CRD42016049911) and written according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Protocols (PRISMA-P) \[[@CR23]\].

Statistical analysis {#Sec3}
--------------------

The analysis was with IBM statistical package for social sciences (IBM SPSS) version 24 (IBM Corp., Armonk, NY) and STATA 9.0 (College Station, TX). We calculated the percentage of trials that scored yes on each of the 16 items and the associated 95% confidence interval (CI).

We reported categorical variables as count and percentages; continuous variables are summarized as mean (standard deviation (SD)) or median (interquartile range (IQR)). Incidence risk ratio (IRR) was calculated to identify factors associated with better reporting. Negative binomial regression was conducted to determine factors associated with better reporting quality.

Results {#Sec4}
=======

Our search identified 228 articles; after the screening, one hundred and thirty-six articles were found to be ineligible based on several reasons (Fig. [1](#Fig1){ref-type="fig"}). A total of 92 articles from 48 journals were eligible; among these, 12 were conference presentations. The three highest contributing journals were *European Journal of Heart Failure* (9 articles; 9.8%), *American Heart Journal* (8 articles; (8.7%), *Journal of American College of Cardiology* (7 articles; 7.6%), and *Journal of Cardiac Failure* (7 articles; 7.6%).Fig. 1Study flow

Study characteristics {#Sec5}
---------------------

The estimate of Kappa statistic for inter-rater agreement for screening publications for eligibility was 0.82 \[95% confidence interval (CI), 0.76--0.87\]. A majority (71%) of the studies were published between 2001 and 2016 (Table [1](#Tab1){ref-type="table"}). Both pharmacological intervention studies and non-pharmacological intervention studies were 45 (49%), respectively; two studies (2%) had both pharmacological and non-pharmacological interventions. The abstract presentation was structured in 80% of the studies. In 62 of 92 (67%) of the studies, the CONSORT statement was not endorsed by the publisher. Most (74%) of the studies were conducted at a single site.Table 1Characteristics of included papers: *n* = 92CharacteristicCount (%)/median (Q1; Q3)Year of publication 1990--200626 (28%) 2007--201666 (72%)Intervention type (*n* = 90) Pharmacological45 (49%) Non-pharmacological45 (49%) Both pharmacological and non-pharmacological2 (2%)Abstract format • Structured74/92 (80%) • Unstructured18/92 (20%)CONSORT endorsement • Yes30/92 (33%) • No62/92 (67%)Number of sites • Single61/82 (74%) • Multiple21/82 (26%)Study duration in months (*n* = 68)3.0 (2.6; 6.1)Sample size (*n* = 88)41 (24; 88)*CONSORT* Consolidated Standards of Reporting Trials, *Q1* first quartile, *Q3* third quartile

Quality of reporting of abstracts of pilot trials {#Sec6}
-------------------------------------------------

None of the studies reported all the 16 items in the checklist (Table [2](#Tab2){ref-type="table"}), the maximum reported number of items was 12, with a mean (SD) of 8.3 (1.7) items. The most reported item was the type of intervention intended for each group 99% (95% CI 91; 99), followed by specified objectives of the pilot trial 94% (95% CI 89; 99) and pre-specified outcome to address pilot trial objectives 97% (95% CI 90; 98).Table 2Publication adherence to CONSORT checklist for abstract of pilot trials *n* = 92ItemCriteriaCountPercent (95% CI)TitleIdentifierTitle identifies the study is a randomized controlled pilot trial6571 (60; 79)DescriptionTrial designDescription of pilot trial design (e.g., parallel or cluster)3033 (23; 44)MethodEligibilityEligibility criteria for each participant8188 (78; 94)SettingsSetting where pilot was conducted2932 (22; 47)InterventionsInterventions intended for each group9199 (91; 99)ObjectivesSpecific objectives of the pilot trial8994 (89; 99)OutcomesPre-specified assessment or measurement to address the pilot trial objectives8997 (90; 98)Randomization sequence generationDescribe how participants were allocated to the interventions1213 (8; 19)Blinding (masking)Whether or not participants, caregivers, and those assessing the outcomes were blinded to group assignment2022 (15; 31)ResultsNumber randomizedNumber of participants screened1516 (9; 26)Number randomized to each group for the pilot objectives4145 (36; 53)RecruitmentTrial status (for conference abstracts)22 (5; 8)Numbers analyzedNumber of participants analyzed in each group of pilot objectives1516 (11; 24)HarmImportant adverse events or side effects2830 (23; 39)ConclusionResult interpretationGeneral interpretation of results of pilot trial8087(76; 93)PlansAny implication for future trial2022 (15; 30)RegistrationTrial registrationRegistration number of trial1213 (7; 21)FundingSource of funding11 (0.16; 6.9)*CI* confidence interval

The least reported item was funding source 1% (95% CI 0.16; 6.9); however, 21 of 92 (22.8%) studies reported funding source in the main manuscript but not in the abstract. Inadequately reported items include the randomization method used 13% (95% CI 8; 19), trial registration information 13% (95% CI 7; 21), and the number of participants screened in each arm 16% (95% CI 9; 26). Recruitment status, an item in the CONSORT checklist that addresses conference presentation, was low with 2% (95% CI 5; 8) among the 12 conference abstracts.

Multivariable analysis (Table [3](#Tab3){ref-type="table"}) of factors associated with reporting quality showed pharmacological intervention is significantly associated with better reporting quality (IRR 0.88; 95% CI 0.81; 0.97; *p* value 0.01), while structured abstract (IRR 1.10; 95% CI 0.99; 1.23; *p* value 0.05) did not have a strong association. Journals which endorsed CONSORT was not a significant factor (IRR 1.10; 95% CI 0.99; 1.23; *p* value 0.06).Table 3Univariate and multivariable analysis of factors associated with reported itemsItemUnivariateMultivariableIRR (95% CI)*p* valueIRR (95% CI)*p* valueYear of publication • 1990--2006\
 • 2007--20160.99 (0.91; 1.08)0.861.07 (0.91; 1.13)0.74Intervention type • Pharmacological\
 • Non-pharmacological0.93 (0.86; 1.01);0.070.88 (0.81; 0.97)0.01Abstract format • Structured\
 • Unstructured1.11 (0.99; 1.24)0.081.10 (0.99; 1.23)0.05CONSORT endorsement • Yes\
 • No1.07 (0.98; 1.16)0.121.10 (0.99; 1.23)0.06Number of sites • Single\
 • Multiple1.08 (0.97; 1.22)0.141.02 (0.92; 1.15)0.62Study duration\*1.03 (1.01; 1.06)0.02Sample size\*1.01 (0.96; 1.07)0.63*IRR* incidence rate ratio, *CI* confidence interval\*Incident rate for change in 1 unit on the log scale

Discussion and conclusions {#Sec7}
==========================

The CONSORT extension for reporting of abstracts of pilot trials was introduced in 2016 to standardize the reporting of abstracts of such studies. We undertook this survey to gauge the current practice using heart failure pilot trials as a sample to track reporting quality improvement expected with introduction and adherence to the extension. We found inadequate reporting quality in keeping with previous articles evaluating adherence to CONSORT checklist on abstracts \[[@CR8], [@CR24], [@CR25]\].

The least reported item was the funding source, similar to findings in a previous study \[[@CR26]\]. The full declaration of funding source in a publication can give the reader the opportunity to make their own assessment regarding potential conflict of interest. However, we noticed that 22/96 of the articles had information on funding in other places rather than the abstract, and this may not be unrelated to word count stipulation by individual journals. Often, this poses a challenge to authors on what to include in abstracts, and there may be the need for CONSORT extension checklist developers to consider this limitation.

The randomization sequence was also poorly reported. It is an item that can provide acceptable comparability between groups if properly reported. Some previous studies have commented on this methodological flaw \[[@CR10], [@CR27]--[@CR29]\], explaining that this could be because of attachment of more relevance to clinical than the methodological aspect of RCTs. There has been corroborating evidence in other studies supporting a correlation between deficient reporting and poor trial methodology \[[@CR30]--[@CR32]\].

Many of the articles were also silent on the blinding, and when used, some failed to state the group blinded in the studies. Not being explicit about blinding erodes the integrity and internal validity of the reports, and it is a potential source of bias among the readers \[[@CR33], [@CR34]\]. Reporting on harm was low at 28%; this is an essential item as it informs the design and applicability of intended larger trials. Previously, this safety reporting has often been inadequate or neglected \[[@CR35]\]. And, in literature, there is highly variable adherence to reporting of harm \[[@CR36], [@CR37]\].

Methodological aspects reported include intervention type, specific objective, and outcomes to be assessed. Many of the articles identified them as pilot trials; this was despite the constraint of word limit by journals, a reason often adduced as responsible for not including this \[[@CR10], [@CR26], [@CR29]\]. Also, pilot trials with pharmacological intervention, those with structured abstracts, and those published in the journal that endorses CONSORT were more likely to report on the items on the checklist. The last point brings to fore why it is important for journals to have stipulated reporting format to ensure that the quality of abstracts' report is improved.

Our study is limited in scope by using only articles published in the English language. We also used a recently produced checklist to evaluate publications done by authors who at the time of writing of the articles probably had no reporting checklist to follow.

In conclusion, the reporting quality of abstracts of heart failure trial measured by the number of items reported was suboptimal; the need to guard against this was the reason that informed the introduction of CONSORT extension checklist. The desire is that increasingly journals will demand adherence to the checklist by authors. Ultimately, we hope that there will be a marked improvement in the quality of report of abstracts in the coming years.
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